The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...
Meanwhile, synthetic gel aids in recovery after spinal surgery; Pittsburgh researchers create helper robots for people with ALS; a study finds nerve stimulation is effective against ...
The field of microbiome research, particularly its interaction with immunotherapy, is rapidly evolving and holds significant promise for enhancing cancer ...
Zacks.com on MSN2d
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host DiseaseMesoblast Limited MESO announced that the FDA has approved Ryoncil (remestemcel-L) for the treatment of steroid-refractory ...
The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...
Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...
More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.
Mesoblast announces that the FDA approved Ryoncil. Ryoncil is the only approved therapy for steroid-refractory acute graft ...
Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...
Silviu and the team at Mesoblast have opened a new chapter in harnessing MSC therapies to treat devastating conditions like SR-aGVHD. This approval validates the immense therapeutic promise of MSCs ...
Mesoblast's Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback